Date | Title | Description | |
---|---|---|---|
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
Pages
Date | Title | Description | |
---|---|---|---|
26 Feb 2020 | Annual Corporate Governance Report | ROVI releases the 2019 Annual Corporate Governance Report | Download |
26 Feb 2020 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors | Download |
26 Feb 2020 | Information on P&L | ROVI releases the press release related to the full year 2019 financial results | Download |
26 Feb 2020 | Information on P&L | ROVI releases the full year 2019 results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
04 Apr 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2019 | Download |
19 Mar 2019 | R&D: new licenses, patents and registered trademarks | ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | Download |
26 Feb 2019 | Informe Anual de Remuneraciones de los Consejeros | ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors | Download |
26 Feb 2019 | Informe Anual de Gobierno Corporativo | ROVI releases the 2018 Annual Corporate Governance Report | Download |
26 Feb 2019 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |